Back to Search Start Over

Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.

Authors :
Siddiqui, Moneeza K
Smith, Gillian
St Jean, Pamela
Dawed, Adem Y
Bell, Samira
Soto-Pedre, Enrique
Kennedy, Gwen
Carr, Fiona
Wallentin, Lars
White, Harvey
Macphee, Colin H
Waterworth, Dawn
Palmer, Colin N A
Siddiqui, Moneeza K
Smith, Gillian
St Jean, Pamela
Dawed, Adem Y
Bell, Samira
Soto-Pedre, Enrique
Kennedy, Gwen
Carr, Fiona
Wallentin, Lars
White, Harvey
Macphee, Colin H
Waterworth, Dawn
Palmer, Colin N A
Publication Year :
2022

Abstract

AIMS/HYPOTHESIS: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has an independent prognostic association with major coronary events (MCE). However, no study has investigated whether type 2 diabetes status modifies the effect of Lp-PLA2 activity or inhibition on the risk of MCE. We investigate the interaction between diabetes status and Lp-PLA2 activity with risk of MCE. Subsequently, we test the resulting hypothesis that diabetes status will play a role in modifying the efficacy of an Lp-PLA2 inhibitor. METHODS: A retrospective cohort study design was utilised in two study populations. Discovery analyses were performed in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort based in Scotland, UK. Participants were categorised by type 2 diabetes control status: poorly controlled (HbA1c ≥ 48 mmol/mol or ≥6.5%) and well-controlled (HbA1c < 48 mmol/mol or <6.5%) diabetes (n = 7420). In a secondary analysis of the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial of Lp-PLA2 inhibitor (darapladib) efficacy, 15,828 participants were stratified post hoc by type 2 diabetes diagnosis status (diabetes or no diabetes) at time of recruitment. Lp-PLA2 activity was then divided into population-specific quartiles. MCE were determined from linked medical records in GoDARTS and trial records in STABILITY. First, the interaction between diabetes control status and Lp-PLA2 activity on the outcome of MCE was explored in GoDARTS. The effect was replicated in the placebo arm of STABILITY. The effect of Lp-PLA2 on MCE was then examined in models stratified by diabetes status. This helped determine participants at higher risk. Finally, the effect of Lp-PLA2 inhibition was assessed in STABILITY in the higher risk group. Cox proportional hazards models adjusted for confounders were used to assess associations. RESULTS: In GoDARTS, a significant interaction between increased Lp-PLA2 activity (continuous

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1312847754
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1007.s00125-021-05574-5